MCID: OST115
MIFTS: 40

Osteonecrosis of the Jaw

Categories: Bone diseases, Oral diseases, Rare diseases

Aliases & Classifications for Osteonecrosis of the Jaw

MalaCards integrated aliases for Osteonecrosis of the Jaw:

Name: Osteonecrosis of the Jaw 59

Classifications:



External Ids:

ICD10 via Orphanet 34 K10.2
UMLS via Orphanet 73 C2711248
Orphanet 59 ORPHA399293

Summaries for Osteonecrosis of the Jaw

MalaCards based summary : Osteonecrosis of the Jaw is related to osteonecrosis and autoimmune disease. An important gene associated with Osteonecrosis of the Jaw is CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Hormones and Zoledronic Acid have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotype is renal/urinary system.

Wikipedia : 75 Osteonecrosis of the jaw (ONJ) is a severe bone disease (osteonecrosis) that affects the jaws (the... more...

Related Diseases for Osteonecrosis of the Jaw

Diseases related to Osteonecrosis of the Jaw via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis 32.8 VEGFA FDPS CYP2C8
2 autoimmune disease 29.8 IL17A HLA-DRB1 HLA-DQB1
3 bacterial infectious disease 29.1 IL17A DEFB4A DEFB103B DEFB1
4 arthritis 29.1 TGFB1 IL17A HLA-DRB1 HLA-DQB1
5 rheumatoid arthritis 29.1 VEGFA TGFB1 IL17A HLA-DRB1 HLA-DQB1
6 gnathodiaphyseal dysplasia 11.3
7 myeloma, multiple 11.0
8 osteoporosis 10.9
9 bone disease 10.9
10 bone mineral density quantitative trait locus 8 10.9
11 bone mineral density quantitative trait locus 15 10.9
12 bone resorption disease 10.9
13 osteomyelitis 10.8
14 mammary paget's disease 10.8
15 rapidly involuting congenital hemangioma 10.7
16 periodontitis 10.6
17 renal cell carcinoma, nonpapillary 10.5
18 corneal abscess 10.4 DEFB4A DEFB1
19 endophthalmitis 10.4 VEGFA DEFB1
20 bone cancer 10.4
21 triiodothyronine receptor auxiliary protein 10.4
22 avascular necrosis 10.4
23 endosteal hyperostosis, autosomal dominant 10.4
24 maxillary sinusitis 10.4
25 kidney cancer 10.4
26 central nervous system vasculitis 10.3 IL17A HLA-DRB1
27 limbic encephalitis with lgi1 antibodies 10.3 HLA-DRB1 HLA-DQB1
28 mucositis 10.3
29 paget's disease of bone 10.3
30 narcolepsy 2 10.3 HLA-DRB1 HLA-DQB1
31 vulvovaginal candidiasis 10.3 DEFB4A DEFB1
32 autoimmune polyglandular syndrome type 3 10.3 HLA-DRB1 HLA-DQB1
33 chronic inflammatory demyelinating polyradiculoneuropathy 10.3 IL17A HLA-DRB1
34 hypersomnia 10.3 HLA-DRB1 HLA-DQB1
35 type ii mixed cryoglobulinemia 10.3 HLA-DRB1 HLA-DQB1
36 lichen planopilaris 10.3 HLA-DRB1 HLA-DQB1
37 metal allergy 10.3 HLA-DRB1 HLA-DQB1
38 recurrent respiratory papillomatosis 10.3 HLA-DRB1 HLA-DQB1
39 breast cancer 10.3
40 brittle bone disorder 10.3
41 thrombophilia 10.3
42 actinomycosis 10.3
43 col1a1/2-related osteogenesis imperfecta 10.3
44 beryllium disease 10.3 HLA-DRB1 HLA-DQB1
45 cystic echinococcosis 10.3 IL17A HLA-DRB1
46 intestinal disease 10.3 VEGFA IL17A DEFB4A
47 chronic beryllium disease 10.3 HLA-DRB1 HLA-DQB1
48 narcolepsy 1 10.3 HLA-DRB1 HLA-DQB1
49 lichen sclerosus 10.3 HLA-DRB1 HLA-DQB1
50 pityriasis rosea 10.2 HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Osteonecrosis of the Jaw:



Diseases related to Osteonecrosis of the Jaw

Symptoms & Phenotypes for Osteonecrosis of the Jaw

MGI Mouse Phenotypes related to Osteonecrosis of the Jaw:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.1 CYP19A1 HLA-DQB1 IL17A SEMA4D TGFB1 VEGFA

Drugs & Therapeutics for Osteonecrosis of the Jaw

Drugs for Osteonecrosis of the Jaw (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hormones Phase 4
2
Zoledronic Acid Approved Phase 3 118072-93-8 68740
3
Denosumab Approved Phase 3 615258-40-7
4
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
5
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
6
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
7 Tocotrienol Investigational Phase 3 6829-55-6
8 Ibandronic Acid Phase 3
9 Bone Density Conservation Agents Phase 3
10 Tocopherols Phase 3
11 Tocotrienols Phase 3
12 Micronutrients Phase 3
13 Trace Elements Phase 3
14 Antioxidants Phase 3
15 Free Radical Scavengers Phase 3
16 Vitamins Phase 3
17 Phosphodiesterase Inhibitors Phase 3
18 Protective Agents Phase 3
19 Nutrients Phase 3
20 Radiation-Protective Agents Phase 3
21 Platelet Aggregation Inhibitors Phase 3
22 Vasodilator Agents Phase 3
23 Mitogens Phase 2, Phase 3
24 Antibodies Phase 1, Phase 2
25 Immunoglobulins Phase 1, Phase 2
26 Antibodies, Monoclonal Phase 1, Phase 2
27 Pharmaceutical Solutions Phase 2
28
Clavulanate Approved, Vet_approved 58001-44-8 5280980
29
Clindamycin Approved, Vet_approved 18323-44-9 29029
30
Amoxicillin Approved, Vet_approved 26787-78-0 33613
31
Phenytoin Approved, Vet_approved 57-41-0 1775
32
Tetracycline Approved, Vet_approved 60-54-8 5353990
33
Pamidronate Approved 40391-99-9 4674
34
Parathyroid hormone Approved, Investigational 9002-64-6
35
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
36
Teriparatide Approved, Investigational 52232-67-4 16133850
37
Alendronate Approved 66376-36-1, 121268-17-5 2088
38
Etidronic acid Approved 2809-21-4, 7414-83-7 3305
39
Risedronate Approved, Investigational 105462-24-6 5245
40
tiludronate Approved, Investigational, Vet_approved 89987-06-4 60937
41
Vitamin D3 Approved, Nutraceutical 67-97-0 6221 5280795
42 Clindamycin palmitate
43 Amoxicillin-Potassium Clavulanate Combination
44 Clindamycin phosphate
45 Antitubercular Agents
46 beta-Lactamase Inhibitors
47 Sodium Channel Blockers
48 Cytochrome P-450 Enzyme Inducers
49 Diuretics, Potassium Sparing
50 Anticonvulsants

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
2 Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases Unknown status NCT00326820 Phase 3 ibandronate sodium;zoledronic acid;Zolendronic Acid
3 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
4 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
5 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment Recruiting NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
6 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw: a Multicenter, Randomized, Clinical Trial Not yet recruiting NCT03390777 Phase 2, Phase 3
7 Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
8 Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE" Not yet recruiting NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
9 Phase I Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM) Unknown status NCT02566681 Phase 1
10 Effect of Denosumab in Reversing Periprosthetic Bone Loss Following Hip Replacement Unknown status NCT02444585 Phase 1 Denosumab
11 Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates Completed NCT00462098 Phase 1
12 Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay. Unknown status NCT02218554
13 Prospective Randomized Clinical Study: Role of Platelet Rich Fibrin (PRF) in the Tooth Extraction Site in the Prevention of Jaw Osteonecrosis on Patients Under Bisphosphonates Therapy Unknown status NCT02198001 tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
14 Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates Unknown status NCT02575157
15 Efficacy and Safety on the Use of Bisphosphonates in Paediatrics Completed NCT04012320
16 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer Completed NCT01325142
17 Trans-PBRN Case-control Study of Osteonecrosis of the Jaws Completed NCT01130389
18 Retrospective Cohort Study of ONJ Completed NCT01201330
19 S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment Completed NCT00874211
20 Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw Completed NCT01998607
21 Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis of the Jaws (BON) Completed NCT00601068
22 Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging Completed NCT00592982
23 Does Topical Phenytoin Enhance Healing Process in Bisphosphonate-related Osteonecrosis of the Mandible. A Uni-blind Clinical Trial Study Completed NCT03269214 Topical Phenytoin 5%
24 Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate Completed NCT03051620 Discontinue alendronate
25 Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer Completed NCT01062503 Zoledronic acid
26 International, Multicenter, Prospective Registry to Collect Data of Treatment Patterns of Patients With Medication-related Osteonecrosis of the Jaw (MRONJ) and Their Outcome Recruiting NCT02932501
27 Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects Recruiting NCT01875458
28 Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction Recruiting NCT02661139
29 The Effects of Bovine Colostrum in Bone Metabolism in Humans Recruiting NCT04040010
30 Does Hyperbaric Oxygen Therapy (HBOT) Reduce Pain, Improve Depression and Impact on Patients' Quality of Life for Those Suffering From Late Radiation Tissue Injury? Recruiting NCT02425215
31 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Recruiting NCT03418454
32 A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway Active, not recruiting NCT01967160
33 Osteonecrosis of the Jaw (ONJ) Case Registry Active, not recruiting NCT01666106
34 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study Active, not recruiting NCT00858585
35 POPULATION PHARMACOMETRICS FOR ASSESSING RISK OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW (BRONJ) Withdrawn NCT02069340 zoledronic acid

Search NIH Clinical Center for Osteonecrosis of the Jaw

Genetic Tests for Osteonecrosis of the Jaw

Anatomical Context for Osteonecrosis of the Jaw

MalaCards organs/tissues related to Osteonecrosis of the Jaw:

41
Bone, Breast, Prostate, Bone Marrow, T Cells, Endothelial, Lung

Publications for Osteonecrosis of the Jaw

Articles related to Osteonecrosis of the Jaw:

(show top 50) (show all 2083)
# Title Authors PMID Year
1
Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw. 38
31403036 2019
2
Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan. 38
30949254 2019
3
Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication). 38
30815046 2019
4
Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw. 38
30949253 2019
5
Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication). 38
30705708 2019
6
Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ). 38
31193410 2019
7
☆Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (5), utility of bone scintigraphy and 18F-FDG PET/CT in early detection and risk assessment of medication-related osteonecrosis of the jaw (secondary publication). 38
30956739 2019
8
Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication). 38
30815045 2019
9
Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report. 38
31202510 2019
10
Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. 38
31125092 2019
11
Bibliometric Analysis of Medication-Related Osteonecrosis of the Jaw: High Citation Rates but Low Evidence. 38
31108060 2019
12
Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. 38
31378564 2019
13
Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study. 38
31425598 2019
14
Medication-Related Osteonecrosis of the Jaws. 38
31425596 2019
15
Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. 38
31410544 2019
16
Treatment of medication-related osteonecrosis of the jaw around dental implant with a once-weekly teriparatide: A case report and literature review. 38
31429640 2019
17
Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review. 38
30406491 2019
18
Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis. 38
31373407 2019
19
Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis. 38
31256803 2019
20
Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study. 38
30929994 2019
21
Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. 38
30854568 2019
22
Comment on "Resolution without surgery of an advanced stage of medication-related osteonecrosis of the jaw (MRONJ) in a patient who could not suspend her treatment for osteoporosis", by Sarmiento (2019). 38
31277903 2019
23
Histatin-1 counteracts the cytotoxic and antimigratory effects of zoledronic acid in endothelial and osteoblast-like cells. 38
30690743 2019
24
Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. 38
30844887 2019
25
Fluorescence-guided bone resection: A histological analysis in medication-related osteonecrosis of the jaw. 38
31387830 2019
26
Pharmacogenomics of osteonecrosis of the jaw. 38
31022475 2019
27
The effects of mechanically loaded osteocytes and inflammation on bone remodeling in a bisphosphonate-induced environment. 38
31301402 2019
28
Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report. 38
31301390 2019
29
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. 38
31329513 2019
30
Treatment of bisphosphonate-related osteonecrosis using platelet-rich plasma: microtomographic, microscopic, and immunohistochemical analyses. 38
31269114 2019
31
Bisphosphonate-related osteonecrosis. Application of adipose-derived stem cells in an experimental murine model. 38
31232388 2019
32
Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges. 38
31325201 2019
33
Quantitative SPECT/CT imaging for medication-related osteonecrosis of the jaw: a preliminary study using volume-based parameters, comparison with chronic osteomyelitis. 38
31342316 2019
34
Ultrasonic Piezoelectric Bone Surgery Combined With Leukocyte and Platelet-Rich Fibrin and Pedicled Buccal Fat Pad Flap in Denosumab-Related Osteonecrosis of the Jaw. 38
31299805 2019
35
Comparison of findings of radiographic and fractal dimension analyses on panoramic radiographs of patients with early-stage and advanced-stage medication-related osteonecrosis of the jaw. 38
31005615 2019
36
Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women. 38
30959190 2019
37
Three-dimensional radiologic-pathologic correlation of medication-related osteonecrosis of the jaw using 3D bone SPECT/CT imaging. 38
31287720 2019
38
Low-Intensity Pulsed Ultrasound Prevents Development of Bisphosphonate-Related Osteonecrosis of the Jaw-Like Pathophysiology in a Rat Model. 38
31006496 2019
39
Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice. 38
31311585 2019
40
Medication-related osteonecrosis of the jaw in a minipig model: Parameters for developing a macroscopic, radiological, and microscopic grading scheme. 38
30952472 2019
41
Quantitation and distribution of metallic elements in sequestra of medication-related osteonecrosis of jaw (MRONJ) using inductively coupled plasma atomic emission spectroscopy and synchrotron radiation X-ray fluorescence analysis. 38
30465092 2019
42
Immediate hyperbaric oxygen after tooth extraction ameliorates bisphosphonate-related osteonecrotic lesion in rats. 38
31257597 2019
43
Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis. 38
31350601 2019
44
Influence of bisphosphonates on clinical features of osteoradionecrosis of the maxilla and mandible. 38
30821889 2019
45
Synthetic Calcium Phosphate Ceramics as a Potential Treatment for Bisphosphonate-Related Osteonecrosis of the Jaw. 38
31174333 2019
46
A case report of bisphosphonate related osteonecrosis of the jaw treated by photodynamic therapy. 38
31022581 2019
47
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? 38
29860712 2019
48
Bisphosphonate use in the horse: what is good and what is not? 38
31234844 2019
49
Denosumab and osteonecrosis of the jaw. 38
31363304 2019
50
Medication-related osteonecrosis of the jaw: A literature review. 38
31109863 2019

Variations for Osteonecrosis of the Jaw

Expression for Osteonecrosis of the Jaw

Search GEO for disease gene expression data for Osteonecrosis of the Jaw.

Pathways for Osteonecrosis of the Jaw

GO Terms for Osteonecrosis of the Jaw

Cellular components related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 VEGFA TGFB1 SEMA4D IL17A DEFB4A DEFB103B
2 clathrin-coated endocytic vesicle membrane GO:0030669 9.32 HLA-DRB1 HLA-DQB1
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-DRB1 HLA-DQB1
4 MHC class II protein complex GO:0042613 9.16 HLA-DRB1 HLA-DQB1
5 Golgi lumen GO:0005796 8.92 TGFB1 DEFB4A DEFB103B DEFB1

Biological processes related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.71 VEGFA TGFB1 SEMA4D
2 chemotaxis GO:0006935 9.69 DEFB4A DEFB103B DEFB1
3 defense response GO:0006952 9.67 DEFB4A DEFB103B DEFB1
4 defense response to Gram-positive bacterium GO:0050830 9.61 DEFB4A DEFB103B DEFB1
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.58 VEGFA TGFB1 SEMA4D
6 mammary gland development GO:0030879 9.55 TGFB1 CYP19A1
7 defense response to Gram-negative bacterium GO:0050829 9.54 DEFB4A DEFB103B DEFB1
8 positive regulation of protein complex assembly GO:0031334 9.52 VEGFA TGFB1
9 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.48 VEGFA TGFB1
10 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.46 HLA-DRB1 HLA-DQB1
11 antimicrobial humoral response GO:0019730 9.43 DEFB4A DEFB103B DEFB1
12 positive chemotaxis GO:0050918 9.33 VEGFA DEFB4A DEFB103B
13 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.32 HLA-DRB1 HLA-DQB1
14 immune response GO:0006955 9.1 SEMA4D IL17A HLA-DRB1 HLA-DQB1 DEFB4A DEFB1
15 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.96 HLA-DRB1 HLA-DQB1

Molecular functions related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.61 VEGFA TGFB1 IL17A
2 peptide antigen binding GO:0042605 9.4 HLA-DRB1 HLA-DQB1
3 steroid hydroxylase activity GO:0008395 9.37 CYP2C8 CYP19A1
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.32 CYP2C8 CYP19A1
5 aromatase activity GO:0070330 9.26 CYP2C8 CYP19A1
6 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
7 chemoattractant activity GO:0042056 9.13 VEGFA DEFB4A DEFB103B
8 CCR6 chemokine receptor binding GO:0031731 8.8 DEFB4A DEFB103B DEFB1

Sources for Osteonecrosis of the Jaw

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....